Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose crossover comparison of orodispersible bilastine, ebastine, and desloratadine versus placebo on histamine-induced wheal and flare in healthy volunteers
2024-516569-35-00Phase 4Completed
- Sponsor
- Faes Farma S.A., A. Menarini Industrie Farmaceutiche Riunite S.r.l.
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of bilastine, eribulin and desloratadine in allergy (4 arms), sponsored by Faes Farma S.A., A. Menarini Industrie Farmaceutiche Riunite S.r.l. Primary endpoint: Onset of action. Started Apr 2025; status: completed.
02
Drugs
bilastineeribulindesloratadine
03
Conditions
allergy
Beyond the preview
Go deeper on 2024-516569-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516569-35-00.